Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News AVAX Technologies Inc (EM) AVXT

Healthcare Biotechnology
AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company’s product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The... see more

Current News (EXPM:AVXT)

DeFi Technologies Announces Q1 2022 Financial Results, with Valour Q1 2022 Net Income of $967,666

PR Newswire May 17, 2022

AVAX Technologies Announces Results Of Its OVAX, Ovarian Cancer Vaccine, Phase 1/2 Clinical Trial In Patients With Relapsed Stage III Or IV Ovarian Cancer.

PR Newswire January 26, 2016

AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer

PR Newswire October 19, 2015

AVAX Announces Settlement Agreement with Cancer Treatment Centers of America and Approves $45 Million Private Placement Financing

Business Wire August 4, 2015

AVAX Technologies Announces Expansion of Clinical Study with Autologous Ovarian Cancer Vaccine (OVax®)

Business Wire February 11, 2014
View More News ››

Opinion & Analysis (EXPM:AVXT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:AVXT)

Be the first to post on this bullboard.

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp. operates as a waste to fuels company, focuses on wood waste byproducts conversion to renewable ...
View More »